Published April 30, 2026 | Version v1

Lassa Fever Encephalitis: Descriptive Review of Neuroinvasion, Neuropathogenesis, Clinical Spectrum, and Therapeutic Challenges

Description

Lassa fever (LF) is an acute zoonotic viral hemorrhagic disease caused by Lassa virus (LASV), an Old-World arenavirus endemic in West Africa and responsible for substantial morbidity and mortality across affected populations. Although the disease has historically been characterized by fever, hemorrhage, hepatic dysfunction, and multiorgan involvement, neurological manifestations are increasingly recognized as major determinants of disease severity and long-term disability. Among these manifestations, Lassa fever encephalitis represents one of the most severe neuroinvasive complications and may present with altered consciousness, seizures, meningoencephalitis, cerebellar dysfunction, neuropsychiatric abnormalities, and persistent neurological sequelae including sensorineural hearing loss.

Recent evidence demonstrating LASV RNA within cerebrospinal fluid (CSF), including in patients without detectable serum viremia, has fundamentally altered understanding of neurological disease pathogenesis and supports direct CNS invasion with compartmentalized neuroinfection. Emerging evidence further implicates endothelial dysfunction, blood–brain barrier disruption, cytokine-mediated neurotoxicity, microglial activation, and immune dysregulation in the development of encephalitic disease.

This descriptive review evaluates the epidemiology, neuropathogenesis, neuroimmunology, neuropathology, clinical spectrum, diagnosis, treatment approaches, prognosis, and future directions of Lassa fever encephalitis using literature published from 2000 to 2026. Despite advances in outbreak surveillance and molecular diagnostics, significant therapeutic limitations remain. Ribavirin continues to represent the principal antiviral intervention despite persistent uncertainty regarding efficacy in established CNS disease. Improved neurodiagnostic capability, CNS-directed therapeutics, and long-term neurological surveillance remain essential for reducing the burden associated with neuroinvasive Lassa fever.

Files

TPCJ2026-13-02-143-163.pdf

Files (853.1 kB)

Name Size Download all
md5:3d87a80b0ac8c61e24175a72189d17b1
853.1 kB Preview Download

Additional details

References

  • [1]. Bausch DG, Hadi CM, Khan SH, Lertora JJ. Review of the literature and proposed guidelines for the use of oral ribavirin as postexposure prophylaxis for Lassa fever. Clin Infect Dis. 2010 Dec 15;51(12):1435-41. doi: 10.1086/657315. Epub 2010 Nov 8. PMID: 21058912; PMCID: PMC7107935.
  • [2]. Ezeomah C, Adoga A, Ihekweazu C, Paessler S, Cisneros I, Tomori O, Walker D. Sequelae of Lassa Fever: Postviral Cerebellar Ataxia. Open Forum Infect Dis. 2019 Dec 3;6(12):ofz512. doi: 10.1093/ofid/ofz512. PMID: 31879673; PMCID: PMC6923636.
  • [3]. John ON, Akyala AI, Eleojo GI, Aremu SO, Matthew AO, Elam OP, Ezeobi AJ, Augustine O, Barnabas S, Augustine U, Ayo OJ, Mohammed K, Ameh AJ, Ohize MS, Thankgod OS, Barkhadle AA. Impact of seasonal changes on the epidemiology of Lassa fever in a state in North Central, Nigeria. Trop Dis Travel Med Vaccines. 2026 Mar 13;12(1):12. doi: 10.1186/s40794-026-00294-3. PMID: 41827052; PMCID: PMC12983630.
  • [4]. Nigeria Centre for Disease Control (NCDC). Lassa Fever Situation Report, Weekly Epidemiological Report. 2025;Week 52.
  • [5]. Okogbenin S, Erameh C, Okoeguale J, Edeawe O, Ekuaze E, Iraoyah K, Agho J, Groger M, Kreuels B, Oestereich L, Babatunde FO, Akhideno P, Günther S, Ramharter M, Omansen T. Two Cases of Lassa Fever Successfully Treated with Ribavirin and Adjunct Dexamethasone for Concomitant Infections. Emerg Infect Dis. 2022 Oct;28(10):2060-2063. doi: 10.3201/eid2810.220625. PMID: 36148915; PMCID: PMC9514364.
  • [6]. Okokhere PO, Erameh CO, Alikah F, Akhideno PE, Iruolagbe CO, Osazuwa OO, Bankole IA, Adomeh DI, Odia I, Aire CO, Oyakhilome J, Agbukor J, Atafo RO, Asogun DA, Happi CT, Sabeti PC, Günther S, Akpede GO. Acute Lassa Virus Encephalitis with Lassa Virus in the Cerebrospinal Fluid but Absent in the Blood: A Case Report with a Positive Outcome. Case Rep Neurol. 2018 Jul 3;10(2):150-158. doi: 10.1159/000490374. PMID: 30057542; PMCID: PMC6062684.
  • [7]. Uppala PK, Karanam SK, Kandra NV, Edhi S. Lassa fever: A comprehensive review of virology, clinical management, and global health implications. World J Virol. 2025 Sep 25;14(3):108405. doi: 10.5501/wjv.v14.i3.108405. PMID: 41025087; PMCID: PMC12476800.
  • [8]. Duvignaud A, Doutchi M, Abejegah C, Etafo I, Jaspard M, Serra B, Tricaud E, Levy-Marchal C, Anglaret X, Ahmed LA, Adedosu AN, Malvy D, Ayodeji OO. Delayed-onset paraparesis in Lassa fever: A case report. Int J Infect Dis. 2020 Mar;92:49-52. doi: 10.1016/j.ijid.2019.12.022. Epub 2019 Dec 19. PMID: 31866549.
  • [9]. Mateer EJ, Huang C, Shehu NY, Paessler S. Lassa fever-induced sensorineural hearing loss: A neglected public health and social burden. PLoS Negl Trop Dis. 2018 Feb 22;12(2):e0006187. doi: 10.1371/journal.pntd.0006187. PMID: 29470486; PMCID: PMC5823363.
  • [10]. Duvignaud A, Jaspard M, Etafo IC, Serra B, Abejegah C, Gabillard D, Doutchi M, Alabi JF, Adedokun MA, Akinpelu AO, Oyegunle OO, Etafo J, Dede AO, Onyechi MN, Ireneh MU, Gbenga-Ayeni O, Fadiminiyi KG, Ehigbor PI, Ouattara E, Levy-Marchal C, Karcher S, N'guessan-Koffi L, Ahyi I, Amani E, Diabaté M, Siloué B, Schaeffer J, Augier A, Ogbaini-Emovon E, Salam AP, Horby P, Ahmed LA, Günther S, Adedosu AN, Anglaret X, Ayodeji OO, Malvy D. Lassa fever clinical course and setting a standard of care for future randomized trials: A protocol for a cohort study of Lassa-infected patients in Nigeria (LASCOPE). Travel Med Infect Dis. 2020 Jul-Aug;36:101557. doi: 10.1016/j.tmaid.2020.101557. Epub 2020 Jan 21. PMID: 31978611; PMCID: PMC7616915.
  • [11]. Penfold S, Adegnika AA, Asogun D, Ayodeji O, Azuogu BN, Fischer WA 2nd, Garry RF, Grant DS, Happi C, N'Faly M, Olayinka A, Samuels R, Sibley J, Wohl DA, Accrombessi M, Adetifa I, Annibaldis G, Camacho A, Dan-Nwafor C, Deha ARE, DeMarco J, Duraffour S, Goba A, Grais R, Günther S, Honvou ÉJJP, Ihekweazu C, Jacobsen C, Kanneh L, Momoh M, Ndiaye A, Nsaibirni R, Okogbenin S, Ochu C, Ogbaini E, Logbo ÉPMA, Sandi JD, Schieffelin JS, Verstraeten T, Vielle NJ, Yadouleton A, Yovo EK; Enable Protocol authorship group. A prospective, multi-site, cohort study to estimate incidence of infection and disease due to Lassa fever virus in West African countries (the Enable Lassa research programme)-Study protocol. PLoS One. 2023 Mar 30;18(3):e0283643. doi: 10.1371/journal.pone.0283643. Erratum in: PLoS One. 2025 Jan 14;20(1):e0317720. doi: 10.1371/journal.pone.0317720. PMID: 36996258; PMCID: PMC10062557.
  • [12]. Warner BM, Safronetz D, Stein DR. Current research for a vaccine against Lassa hemorrhagic fever virus. Drug Des Devel Ther. 2018 Aug 14;12:2519-2527. doi: 10.2147/DDDT.S147276. PMID: 30147299; PMCID: PMC6097522.
  • [13]. Cai Y, Ye C, Cheng B, Nogales A, Iwasaki M, Yu S, Cooper K, Liu DX, Hart R, Adams R, Brady T, Postnikova EN, Kurtz J, St Claire M, Kuhn JH, de la Torre JC, Martínez-Sobrido L. A Lassa Fever Live-Attenuated Vaccine Based on Codon Deoptimization of the Viral Glycoprotein Gene. mBio. 2020 Feb 25;11(1):e00039-20. doi: 10.1128/mBio.00039-20. PMID: 32098811; PMCID: PMC7042690.
  • [14]. Lukashevich IS, Pushko P. Vaccine platforms to control Lassa fever. Expert Rev Vaccines. 2016 Sep;15(9):1135-50. doi: 10.1080/14760584.2016.1184575. Epub 2016 May 24. PMID: 27136941.
  • [15]. oyessa AB, Maximore L, Keller D, Dogba J, Pajibo M, Johnson K, Saydee E, Monday J, Tuopileyi R 2nd, Mahmoud N. Lesson learned from the investigation and response of Lassa fever outbreak, Margibi County, Liberia, 2018: case report. BMC Infect Dis. 2019 Jul 11;19(1):610. doi: 10.1186/s12879-019-4257-z. PMID: 31296177; PMCID: PMC6624965.
  • [16]. Salu OB, Amoo OS, Shaibu JO, Abejegah C, Ayodeji O, Musa AZ, Idigbe I, Ezechi OC, Audu RA, Salako BL, Omilabu SA. Monitoring of Lassa virus infection in suspected and confirmed cases in Ondo State, Nigeria. Pan Afr Med J. 2020 Aug 6;36:253. doi: 10.11604/pamj.2020.36.253.22104. PMID: 33014249; PMCID: PMC7519794.
  • [17]. Ogunkunle TO, Bello SO, Anderson CI, Musa R, Olaosebikan R, Imam A. Fatal case of newborn Lassa fever virus infection mimicking late onset neonatal sepsis: a case report from northern Nigeria. Infect Dis Poverty. 2020 Aug 10;9(1):110. doi: 10.1186/s40249-020-00731-1. PMID: 32778167; PMCID: PMC7418325.
  • [18]. Raabe VN, Kann G, Ribner BS, Morales A, Varkey JB, Mehta AK, Lyon GM, Vanairsdale S, Faber K, Becker S, Eickmann M, Strecker T, Brown S, Patel K, De Leuw P, Schuettfort G, Stephan C, Rabenau H, Klena JD, Rollin PE, McElroy A, Ströher U, Nichol S, Kraft CS, Wolf T; Emory Serious Communicable Diseases Unit. Favipiravir and Ribavirin Treatment of Epidemiologically Linked Cases of Lassa Fever. Clin Infect Dis. 2017 Sep 1;65(5):855-859. doi: 10.1093/cid/cix406. PMID: 29017278; PMCID: PMC5682919
  • [19]. Agboeze J, Nwali MI, Nwakpakpa E, Ogah OE, Onoh R, Eze J, Ukaegbe C, Ajayi N, Nnadozie UU, Orji ML, Ojide KC, Unigwe SU, Chika-Igwenyi N, Nwidi DU, Clement CU, Kalombo C, Makwe C, Tshiang J. Lassa fever in pregnancy with a positive maternal and fetal outcome: A case report. Int J Infect Dis. 2019 Dec;89:84-86. doi: 10.1016/j.ijid.2019.08.023. Epub 2019 Aug 26. PMID: 31465848.
  • [20]. Veldkamp PJ, Schippers EF. Een man met fatale Lassa-koorts na een verblijf in Sierra Leone [A man with fatal Lassa fever following a stay in Sierra Leone]. Ned Tijdschr Geneeskd. 2002 Nov 16;146(46):2201-4. Dutch. PMID: 12467165.
  • [21]. Khan SH, Goba A, Chu M, Roth C, Healing T, Marx A, Fair J, Guttieri MC, Ferro P, Imes T, Monagin C, Garry RF, Bausch DG; Mano River Union Lassa Fever Network. New opportunities for field research on the pathogenesis and treatment of Lassa fever. Antiviral Res. 2008 Apr;78(1):103-15. doi: 10.1016/j.antiviral.2007.11.003. Epub 2007 Dec 17. PMID: 18241935.
  • [22]. Jordan R, Archin NM, Cagno V, Feng JY, Guo H, Herrero LJ, Janeba Z, Meanwell NA, Moffat J, Neyts J, Rocha-Pereira J, Seley-Radtke KL, Sheahan TP, Spengler JR, Welch SR, Xie X, Zakaryan H, Schang LM, Durantel D. Meeting report: 38th international conference on antiviral research in Las Vegas, United States of America, March 17-21, 2025. Antiviral Res. 2025 Sep;241:106222. doi: 10.1016/j.antiviral.2025.106222. Epub 2025 Jul 3. PMID: 40617260; PMCID: PMC12764182.
  • [23]. Abdulkarim MA, Babale SM, Umeokonkwo CD, Bamgboye EA, Bashorun AT, Usman AA, Balogun MS. Epidemiology of Lassa Fever and Factors Associated with Deaths, Bauchi State, Nigeria, 2015-2018. Emerg Infect Dis. 2020 Apr;26(4):799-801. doi: 10.3201/eid2604.190678. PMID: 32186504; PMCID: PMC7101116.
  • [24]. Ehichioya DU, Dellicour S, Pahlmann M, Rieger T, Oestereich L, Becker-Ziaja B, Cadar D, Ighodalo Y, Olokor T, Omomoh E, Oyakhilome J, Omiunu R, Agbukor J, Ebo B, Aiyepada J, Ebhodaghe P, Osiemi B, Ehikhametalor S, Akhilomen P, Airende M, Esumeh R, Muoebonam E, Giwa R, Ekanem A, Igenegbale G, Odigie G, Okonofua G, Enigbe R, Omonegho Yerumoh E, Pallasch E, Bockholt S, Kafetzopoulou LE, Duraffour S, Okokhere PO, Akpede GO, Okogbenin SA, Odia I, Aire C, Akpede N, Tobin E, Ogbaini-Emovon E, Lemey P, Adomeh DI, Asogun DA, Günther S. Phylogeography of Lassa Virus in Nigeria. J Virol. 2019 Oct 15;93(21):e00929-19. doi: 10.1128/JVI.00929-19. PMID: 31413134; PMCID: PMC6803284.
  • [25]. Salami K, Gouglas D, Schmaljohn C, Saville M, Tornieporth N. A review of Lassa fever vaccine candidates. Curr Opin Virol. 2019 Aug;37:105-111. doi: 10.1016/j.coviro.2019.07.006. Epub 2019 Aug 28. PMID: 31472333.
  • [26]. Idemyor V. Lassa virus infection in Nigeria: clinical perspective overview. J Natl Med Assoc. 2010 Dec;102(12):1243-6. doi: 10.1016/s0027-9684(15)30780-x. PMID: 21287906.
  • [27]. Tambo E, Adetunde OT, Olalubi OA. Re-emerging Lassa fever outbreaks in Nigeria: Re-enforcing "One Health" community surveillance and emergency response practice. Infect Dis Poverty. 2018 Apr 28;7(1):37. doi: 10.1186/s40249-018-0421-8. PMID: 29703243; PMCID: PMC5923006.
  • [28]. Ashcroft JW, Olayinka A, Ndodo N, Lewandowski K, Curran MD, Nwafor CD, Madubuike K, Bagnall H, Musa AS, Ahmad A, Akinpelu A, Adeleye A, Martin C, Akano A, Onoja M, Iniobong A, Ukponu W, Arinze C, Ilori E, Mba N, Gannon B, Ahumibe A, Ihekweazu C. Pathogens that Cause Illness Clinically Indistinguishable from Lassa Fever, Nigeria, 2018. Emerg Infect Dis. 2022 May;28(5):994-997. doi: 10.3201/eid2805.211153. Epub 2022 Feb 28. PMID: 35226800; PMCID: PMC9045454.
  • [29]. Ogundele GO, Jolayemi KO, Bello S. Lassa fever in West Africa: a systematic review and meta-analysis of attack rates, case fatality rates and risk factors. BMC Public Health. 2025 Aug 27;25(1):2948. doi: 10.1186/s12889-025-24377-6. PMID: 40866826; PMCID: PMC12382145.
  • [30]. Wada YH, Ogunyinka IA, Yusuff KB, Ochu CL, Yahaya M, Khalid GM, Mutalub YB, Adeniye SB. Knowledge of Lassa fever, its prevention and control practices and their predictors among healthcare workers during an outbreak in Northern Nigeria: A multi-centre cross-sectional assessment. PLoS Negl Trop Dis. 2022 Mar 14;16(3):e0010259. doi: 10.1371/journal.pntd.0010259. PMID: 35286303; PMCID: PMC9045733.
  • [31]. Cadmus S, Akinseye V, Cadmus E, Famokun G, Fagbemi S, Ogunde G, Philip A, Ansumana R, Ayinmode A, Taiwo O, Oluwayelu D, Tomori O, Odemuyiwa S. Drivers of Lassa fever in an endemic area of southwestern Nigeria (2017-2021): An epidemiological study. PLoS One. 2025 Jun 25;20(6):e0327143. doi: 10.1371/journal.pone.0327143. PMID: 40561161; PMCID: PMC12193570.
  • [32]. Saka SA, Ojo DO, Mezu NM, Uzuegbu CO, Ighodaro O, Illoh OO, Emekolom ON, Akpa OA, Obiora EA, Muogbo AP. Knowledge, perception and preventive practices of Lassa fever among mothers of under-five children in an endemic community in Edo State, Nigeria. BMC Public Health. 2025 Mar 3;25(1):837. doi: 10.1186/s12889-025-22057-z. PMID: 40033294; PMCID: PMC11874641.
  • [33]. Tiamiyu AB, Adegbite OA, Freides O, Frndak S, Mohammed SS, Broach E, Lombardi K, Anyebe V, Akiga R, Okeke NC, Feyisayo JE, Ugwuezumba O, Akinde C, Osuji A, Agu N, Analogbei T, Ekweremadu C, Bartolanzo D, Prins P, Fan Y, Emekaili D, Abah F, Chiwetelu V, Dike P, Isaiah E, Ayogu M, Ogunkelu E, Agbaim UC, Bukunmi A, Adamu Y, Mebrahtu T, Zuppe A, Johnston M, Modjarrad K, Meri H, Parker Z, Akinwale E, McCauley MD, Schluck G, King DB, Eller LA, Okeji N, Ayemoba OR, Collins ND, Iroezindu MO, Hakre S; EID023 Lassa study team. Seroprevalence and risk factors for Lassa virus infection in South-West and North-Central Nigeria: a community-based cross-sectional study. BMC Infect Dis. 2024 Oct 8;24(1):1118. doi: 10.1186/s12879-024-09954-1. PMID: 39375602; PMCID: PMC11460173.
  • [34]. Asogun DA, Adomeh DI, Ehimuan J, Odia I, Hass M, Gabriel M, Olschläger S, Becker-Ziaja B, Folarin O, Phelan E, Ehiane PE, Ifeh VE, Uyigue EA, Oladapo YT, Muoebonam EB, Osunde O, Dongo A, Okokhere PO, Okogbenin SA, Momoh M, Alikah SO, Akhuemokhan OC, Imomeh P, Odike MA, Gire S, Andersen K, Sabeti PC, Happi CT, Akpede GO, Günther S. Molecular diagnostics for lassa fever at Irrua specialist teaching hospital, Nigeria: lessons learnt from two years of laboratory operation. PLoS Negl Trop Dis. 2012;6(9):e1839. doi: 10.1371/journal.pntd.0001839. Epub 2012 Sep 27. PMID: 23029594; PMCID: PMC3459880.
  • [35]. Happi AN, Olumade TJ, Ogunsanya OA, Sijuwola AE, Ogunleye SC, Oguzie JU, Nwofoke C, Ugwu CA, Okoro SJ, Otuh PI, Ngele LN, Ojo OO, Adelabu A, Adeleye RF, Oyejide NE, Njaka CS, Heeney JL, Happi CT. Increased Prevalence of Lassa Fever Virus-Positive Rodents and Diversity of Infected Species Found during Human Lassa Fever Epidemics in Nigeria. Microbiol Spectr. 2022 Aug 31;10(4):e0036622. doi: 10.1128/spectrum.00366-22. Epub 2022 Aug 1. PMID: 35913205; PMCID: PMC9430508.
  • [36]. Asogun D, Arogundade B, Unuabonah F, Olugbenro O, Asogun J, Aluede F, Ehichioya D. A Review of the Epidemiology of Lassa Fever in Nigeria. Microorganisms. 2025 Jun 18;13(6):1419. doi: 10.3390/microorganisms13061419. PMID: 40572307; PMCID: PMC12196193.
  • [37]. Grace JA, Egoh IJ, Udensi N. Epidemiological trends of Lassa fever in Nigeria from 2015-2021: A review. Ther Adv Infect Dis. 2021 Nov 29;8:20499361211058252. doi: 10.1177/20499361211058252. PMID: 34868582; PMCID: PMC8637796.
  • [38]. Wei, Q., Zhang, T., & Schmit, N. (2026). Post-acute sequelae after Lassa fever: A systematic review and meta-analysis. Journal of Infection, 92(5), 106743. https://doi.org/10.1016/j.jinf.2026.106743
  • [39]. alam AP, Cheng V, Edwards T, Olliaro P, Sterne J, Horby P. Time to reconsider the role of ribavirin in Lassa fever. PLoS Negl Trop Dis. 2021 Jul 8;15(7):e0009522. doi: 10.1371/journal.pntd.0009522. PMID: 34237063; PMCID: PMC8266111.
  • [40]. Haas WH, Breuer T, Pfaff G, Schmitz H, Köhler P, Asper M, Emmerich P, Drosten C, Gölnitz U, Fleischer K, Günther S. Imported Lassa fever in Germany: surveillance and management of contact persons. Clin Infect Dis. 2003 May 15;36(10):1254-8. doi: 10.1086/374853. Epub 2003 May 9. PMID: 12746770.
  • [41]. Cheng HY, French CE, Salam AP, Dawson S, McAleenan A, McGuinness LA, Savović J, Horby PW, Sterne JAC. Lack of Evidence for Ribavirin Treatment of Lassa Fever in Systematic Review of Published and Unpublished Studies1. Emerg Infect Dis. 2022 Aug;28(8):1559-1568. doi: 10.3201/eid2808.211787. PMID: 35876478; PMCID: PMC9328902.
  • [42]. Merson L, Bourner J, Jalloh S, Erber A, Salam AP, Flahault A, Olliaro PL. Clinical characterization of Lassa fever: A systematic review of clinical reports and research to inform clinical trial design. PLoS Negl Trop Dis. 2021 Sep 21;15(9):e0009788. doi: 10.1371/journal.pntd.0009788. PMID: 34547033; PMCID: PMC8486098.
  • [43]. McEntire CRS, Song KW, McInnis RP, Rhee JY, Young M, Williams E, Wibecan LL, Nolan N, Nagy AM, Gluckstein J, Mukerji SS, Mateen FJ. Neurologic Manifestations of the World Health Organization's List of Pandemic and Epidemic Diseases. Front Neurol. 2021 Feb 22;12:634827. doi: 10.3389/fneur.2021.634827. PMID: 33692745; PMCID: PMC7937722.
  • [44]. Bransfield, RC., 2025. The Association between Infectious Diseases, Mental Impairments, Violent Behavior, and Global Instability. Medical Research Archives, [online] 13(1). https://doi.org/10.18103/mra.v13i1.6178
  • [45]. Reyna RA, Littlefield KE, Shehu N, Makishima T, Maruyama J, Paessler S. The Importance of Lassa Fever and Its Disease Management in West Africa. Viruses. 2024 Feb 7;16(2):266. doi: 10.3390/v16020266. PMID: 38400041; PMCID: PMC10892767.
  • [46]. Raabe, V., Mehta, A. K., Evans, J. D., Beitscher, A., Bhadelia, N., Brett-Major, D., Cieslak, T. J., Davey, R. T., Evans, J. D., Frank, M. G., Iwen, P., Kortepeter, M. G., Levine, C., McLellan, S., Mehta, A. K., Sauer, L., Shenoy, E. S., & Zachary, K. (2022). Lassa virus infection: A summary for clinicians. International Journal of Infectious Diseases, 119, 187–200. https://doi.org/10.1016/j.ijid.2022.04.004
  • [47]. Oli AN, Chukwuma IF, Nwonu EJ, et al. A concise review on Lassa fever infection and its prevention strategies. Authorea; 2025. DOI: 10.22541/au.176304083.36084157/v1.
  • [48]. NETEC. Lassa Fever Outbreak in Nigeria (2026 Update) [Internet]. April 3, 2026. Available from: https://netec.org/2026/04/03/special-pathogen-of-concern-lassa-fever-outbreak-in-nigeria-2026-update/
  • [49]. Okokhere P, Colubri A, Azubike C, Iruolagbe C, Osazuwa O, Tabrizi S, Chin E, Asad S, Ediale E, Rafiu M, Adomeh D, Odia I, Atafo R, Aire C, Okogbenin S, Pahlman M, Becker-Ziaja B, Asogun D, Fradet T, Fry B, Schaffner SF, Happi C, Akpede G, Günther S, Sabeti PC. Clinical and laboratory predictors of Lassa fever outcome in a dedicated treatment facility in Nigeria: a retrospective, observational cohort study. Lancet Infect Dis. 2018 Jun;18(6):684-695. doi: 10.1016/S1473-3099(18)30121-X. Epub 2018 Mar 6. Erratum in: Lancet Infect Dis. 2018 May;18(5):492. doi: 10.1016/S1473-3099(18)30208-1. PMID: 29523497; PMCID: PMC5984133.
  • [50]. World Health Organization. Lassa fever - Fact Sheet [Internet]. Geneva: WHO; 2024 Dec 5. Available from: https://www.who.int/news-room/fact-sheets/detail/lassa-fever
  • [51]. Chika-Igwenyi NM, Harrison RE, Psarra C, Gil-Cuesta J, Gulamhusein M, Onwe EO, Onoh RC, Unigwe US, Ajayi NA, Nnadozie UU, Ojide CK, Nwidi DU, Ezeanosike O, Sampson E, Adeke AS, Ugwu CN, Anebonam U, Tshiang JK, Maikere J, Reid A. Early onset of neurological features differentiates two outbreaks of Lassa fever in Ebonyi state, Nigeria during 2017-2018. PLoS Negl Trop Dis. 2021 Mar 8;15(3):e0009169. doi: 10.1371/journal.pntd.0009169. PMID: 33684118; PMCID: PMC7984835.
  • [52]. Shredder B, et al. Presence of Lassa Virus RNA in Cerebrospinal Fluid (CSF) of pediatric LF patients. J Infect Dis. 2025.
  • [53]. U University of Nebraska Medical Center. Study warns of underrecognized Lassa fever threat with global implications [Internet]. 2026 Mar 4. Available from: https://www.unmc.edu/healthsecurity/transmission/2026/03/04/study-warns-of-underrecognized-lassa-fever-threat-with-global-implications/
  • [54]. Ehichioya D, et al. Acute Lassa Virus Encephalitis with Lassa Virus in the CSF. Case Rep Infect Dis. 2018.
  • [55]. Centers for Disease Control and Prevention (CDC). About Lassa Fever [Internet]. 2025 Jan 31. Available from: https://www.cdc.gov/lassa-fever/about/index.html
  • [56]. Saka SA, Lawal QO, Otaigbe O, Blackie FF, Ighodaro O, Odafen PI, Okogbenin S. Lassa fever survivors: long-term health effects and chronic sequelae - a scoping review. BMC Infect Dis. 2025 Jul 1;25(1):823. doi: 10.1186/s12879-025-11262-1. PMID: 40597771; PMCID: PMC12210993.
  • [57]. Besson ME, Pépin M, Metral PA. Lassa Fever: Critical Review and Prospects for Control. Trop Med Infect Dis. 2024 Aug 14;9(8):178. doi: 10.3390/tropicalmed9080178. PMID: 39195616; PMCID: PMC11359316.
  • [58]. Lassa Virus (LASV) [Internet]. GeneTex. [cited 2026 May 18]. Available from: https://www.genetex.com/Research/Overview/infectious_diseases/Lassa-Virus?utm_source
  • [59]. Cheng, B. Y., Ortiz-Riaño, E., de la Torre, J. C., Martínez-Sobrido, L. Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells. J. Vis. Exp. (78), e50662, doi:10.3791/50662 (2013).
  • [60]. Accessed online on May 18th, 2026. Available from: https://upload.wikimedia.org/wikipedia/commons/6/69/Lassa_virus.JPG?utm_source=commons.wikimedia.org&utm_campaign=index&utm_content=original
  • [61]. Jan, S., Phadke, K.S., Lam, V.L. et al. Lassa virus protein–protein interactions as mediators of Lassa fever pathogenesis. Virol J 22, 52 (2025). https://doi.org/10.1186/s12985-025-02669-y
  • [62]. Garry, R.F. Lassa fever — the road ahead. Nat Rev Microbiol 21, 87–96 (2023). https://doi.org/10.1038/s41579-022-00789-8
  • [63]. Ryu WS. Other Negative-Strand RNA Viruses. In: Molecular virology of human pathogenic viruses [Internet]. Amsterdam: Academic Press; 2017 [cited 2026 May 18]. Chapter 16; p. 213-224. Available from: ScienceDirect doi: 10.1016/B978-0-12-800838-6.00016-0 [1, 3, 4]